Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma

This study tests a triple combination approach — hepatic arterial infusion chemotherapy (HAIC, delivered directly to liver tumors), lenvatinib (an oral targeted therapy), and cadonilimab (an immunotherapy) — to shrink unresectable liver cancer (hepatocellular carcinoma) enough to allow surgery. **You may be eligible if...** - You are 18 or older and have been diagnosed with hepatocellular carcinoma (HCC), confirmed by biopsy or standard imaging criteria - Your cancer currently cannot be removed by surgery - You are in good general health (ECOG performance status 0 or 1) - Your liver function is adequate **You may NOT be eligible if...** - Your cancer has spread to distant organs beyond the liver (extensive metastases) - You have serious heart, kidney, or clotting problems - You have uncontrolled autoimmune disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.